Omega Interferon Alone or in Combination With Ribavirin in Subjects With Hepatitis C

This study has been completed.
Sponsor:
Information provided by:
Intarcia Therapeutics
ClinicalTrials.gov Identifier:
NCT00097045
First received: November 17, 2004
Last updated: August 21, 2007
Last verified: August 2007
  Purpose

This study is designed to compare the safety, tolerability and antiviral effects of omega interferon administered alone to omega interferon administered with ribavirin in the treatment of subjects with chronic Hepatitis C virus (HCV) infection.


Condition Intervention Phase
Hepatitis C
Drug: omega interferon
Drug: Ribavirin
Phase 2

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: Phase 2 Study of Omega Interferon Alone or in Combination With Ribavirin in Subjects With Hepatitis C

Resource links provided by NLM:


Further study details as provided by Intarcia Therapeutics:

Primary Outcome Measures:
  • HCV RNA levels at clinically relevant timepoints

Estimated Enrollment: 90
Study Start Date: November 2004
Study Completion Date: December 2006
Detailed Description:

Omega interferon is administered subcutaneously daily for up to 48 weeks.

  Eligibility

Ages Eligible for Study:   18 Years to 64 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Male or female
  • Age 18 years to 64 years
  • Signed and dated written informed consent form
  • Infection with HCV genotype 1
  • Two HCV RNA levels greater than or equal to 100,000 International Units per mL (IU/mL) at least seven days apart within 6 weeks prior to randomization
  • One alanine aminotransferase level greater than the upper limit of normal between three months and twelve months prior to randomization
  • At least one alanine aminotransferase level greater than the upper limit of normal between three months and twelve months prior to randomization
  • For the duration of treatment with study drug for all subjects and for the duration of treatment with study drug plus an additional six months for subjects who take ribavirin, attenuation of the potential of the subject to become pregnant, or to impregnate a sexual partner, by either:

    1. the use of an approved contraceptive method (e.g., IUD, oral contraceptive, or double-barrier method), or
    2. definitive exclusion by surgery, radiation, menopause or vasectomy
  • For women of childbearing potential, negative serum Beta HCG pregnancy test within 14 days prior to randomization

Exclusion Criteria:

  • Any additional plausible cause for chronic liver disease, including active infection by other viruses known or suspected to cause hepatitis
  • Ascites or other current evidence of portal hypertension
  • Child-Pugh classification B or C liver disease
  • Clinically apparent jaundice or a total bilirubin exceeding 2 mg/dL (Subjects with Gilbert's Syndrome who meet all other inclusion and exclusion criteria may be admitted to the study with a total bilirubin greater than 2 mg/dL)
  • Hemoglobin <12 g/dL
  • A platelet count of less than 100,000 per mm3
  • A total white blood cell count of less than 3,000 per mm3
  • An absolute neutrophil count of less than 1,500 per mm3
  • Abnormal thyroid function (Subjects requiring thyroid replacement and who have stable, normal thyroid function may be admitted to the study)
  • History of significant renal dysfunction
  • History of significant or unstable cardiac disease
  • Concurrent alcohol abuse or illicit drug use
  • Pregnant or lactating women
  • Male partners of women who are pregnant
  • Prior usage of an interferon
  • Concurrent usage of any antiviral therapy, including another interferon, during the study
  • Any concurrent infectious disease requiring antimicrobial treatment
  • Positive test for human immunodeficiency virus
  • Positive test for illicit drugs
  • A history of malignancy (except for previously cured squamous cell or basal cell carcinoma)
  • Known hypersensitivity to interferons or ribavirin or related compounds
  • A concurrent diagnosis of depression that has not been stable for at least 60 days prior to randomization
  • Usage of an investigational drug within the 30 days prior to randomization; or the planned usage of an investigational drug other than omega interferon during the course of the current study
  • Prior randomization to this study
  • Any condition which, at the discretion of the investigator, would render an individual an inappropriate candidate for this study
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00097045

Locations
Russian Federation
Moscow, Russian Federation
Smolensk, Russian Federation
St. Petersburg, Russian Federation
Sponsors and Collaborators
Intarcia Therapeutics
  More Information

No publications provided

ClinicalTrials.gov Identifier: NCT00097045     History of Changes
Other Study ID Numbers: Biomed 510-CLP-07
Study First Received: November 17, 2004
Last Updated: August 21, 2007
Health Authority: United States: Food and Drug Administration

Keywords provided by Intarcia Therapeutics:
Hepatitis C
HCV
Omega Interferon
Interferon
HCV genotype 1

Additional relevant MeSH terms:
Hepatitis
Hepatitis A
Hepatitis C
Liver Diseases
Digestive System Diseases
Hepatitis, Viral, Human
Virus Diseases
Enterovirus Infections
Picornaviridae Infections
RNA Virus Infections
Flaviviridae Infections
Interferon omega 1
Interferons
Interferon Type I
Ribavirin
Antineoplastic Agents
Therapeutic Uses
Pharmacologic Actions
Antiviral Agents
Anti-Infective Agents
Antimetabolites
Molecular Mechanisms of Pharmacological Action

ClinicalTrials.gov processed this record on April 21, 2014